Clinical Trials Browser

INDUSTRY × Doxorubicin × 30 days × Clear all

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04623541 2026-06-02

EPCORE™ CLL-1

Phase 1/2 Active not recruiting

194 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04663347 2026-06-02

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

543 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-06-02

EPCORE™FL-2

Phase 3 Recruiting

1,095 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06815575 2026-06-02

A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

Phase 1 Recruiting

53 enrolled

Other solid neoplasm

Solid Tumours

NCT06966700 2026-06-01

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3 Recruiting

2,400 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06717347 2026-05-29

MK-2140-010

Phase 3 Recruiting

1,046 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-05-29

MK-2140-011

Phase 2 Recruiting

594 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07286331 2026-05-27

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

Phase 3 Not yet recruiting

600 enrolled

Gynecologic

Endometrial Neoplasms

NCT06340568 2026-05-20

Fern-EC-01

Phase 3 Recruiting

480 enrolled

Gynecologic

Endometrial Neoplasms

NCT06797635 2026-05-20

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Phase 2 Recruiting

372 enrolled

Breast

Breast Neoplasms

NCT06911502 2026-05-20

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Phase 3 Recruiting

400 enrolled

Lymphoid

Lymphoma, Follicular

NCT07044336 2026-05-20

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Phase 3 Recruiting

700 enrolled

Gynecologic

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

NCT06091254 2026-05-19

OLYMPIA-1

Phase 3 Recruiting

822 enrolled

Lymphoid

Lymphoma, Follicular

NCT06088290 2026-05-15

SaLuDo

Phase 3 Active not recruiting

455 enrolled

Sarcoma

Leiomyosarcoma, Neoplasms

NCT06091865 2026-05-15

OLYMPIA-3

Phase 3 Recruiting

904 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

EPCORE™ NHL-3

EPCORE™ CLL-1

EPCORE™ NHL-2

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

EPCORE™FL-2

A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

MK-2140-010

MK-2140-011

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

Fern-EC-01

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

OLYMPIA-1

SaLuDo

OLYMPIA-3